Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2020 pubmed 130 citations

Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis.

Cau. Laura L; Williams. Michael R MR; Butcher. Anna M AM; Nakatsuji. Teruaki T; Kavanaugh. Jeffrey S JS; Cheng. Joyce Y JY; Shafiq. Faiza F; Higbee. Kyle K; Hata. Tissa R TR; Horswill. Alexander R AR; Gallo. Richard L RL

Key Findings

  • S. epidermidis produces a cysteine protease (EcpA) that degrades desmoglein‑1 and LL‑37
  • EcpA activity correlates with increased skin inflammation and atopic dermatitis severity
  • S. hominis can inhibit EcpA production, suggesting a protective microbial interaction

Practical Outcomes

  • Limit overgrowth of S. epidermidis on the skin, possibly through targeted probiotics or hygiene practices, and consider using S. hominis–based products to suppress harmful protease activity. Supporting the skin barrier and preserving LL‑37 may help reduce inflammation in atopic dermatitis.

Summary

The study found that a common skin bacterium, Staphylococcus epidermidis, can produce a protease called EcpA that breaks down important skin proteins and the antimicrobial peptide LL‑37, worsening atopic dermatitis. In some patients, higher levels of this enzyme were linked to more severe skin symptoms, while another skin microbe, Staphylococcus hominis, can suppress EcpA production.

Abstract

Staphylococcus aureus and Staphylococcus epidermidis are the most abundant bacteria found on the skin of patients with atopic dermatitis (AD). S aureus is known to exacerbate AD, whereas S epidermidis has been considered a beneficial commensal organism. In this study, we hypothesized that S epidermidis could promote skin damage in AD by the production of a protease that damages the epidermal barrier. The protease activity of S epidermidis isolates was compared with that of other staphylococcal species. The capacity of S epidermidis to degrade the barrier and induce inflammation was examined by using human keratinocyte tissue culture and mouse models. Skin swabs from atopic and healthy adult subjects were analyzed for the presence of S epidermidis genomic DNA and mRNA. S epidermidis strains were observed to produce strong cysteine protease activity when grown at high density. The enzyme responsible for this activity was identified as EcpA, a cysteine protease under quorum sensing control. EcpA was shown to degrade desmoglein-1 and LL-37 in vitro, disrupt the physical barrier, and induce skin inflammation in mice. The abundance of S epidermidis and expression of ecpA mRNA were increased on the skin of some patients with AD, and this correlated with disease severity. Another commensal skin bacterial species, Staphylococcus hominis, can inhibit EcpA production by S epidermidis. S epidermidis has commonly been regarded as a beneficial skin microbe, whereas S aureus has been considered deleterious. This study suggests that the overabundance of S epidermidis found on some atopic patients can act similarly to S aureus and damage the skin by expression of a cysteine protease.

Study Information

Provider

pubmed

Year

2020

Date

2020-07-04T00:00:00.000Z

DOI

10.1016/j.jaci.2020.06.024

Citations

130

References

87